Seroatlas · Human Serome Atlas

SLC7A6

Y+L amino acid transporter 2

Also known as: KIAA0245, LAT-2, LAT3, y+LAT-2, YLAT2_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q92536
Gene: SLC7A6
Ensembl: ENSG00000103064
Chromosome: 16
Canonical length: 515 aa
Protein class: Metabolic proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters
Subcellular location: Vesicles,Plasma membrane

OverviewNCBI Gene

Enables L-lysine:L-arginine antiporter activity and arginine binding activity. Involved in L-arginine transmembrane transport; L-leucine transport; and ornithine transport. Predicted to be located in plasma membrane. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

515 residues, UniProt reviewed canonical sequence.

>Q92536|SLC7A6
     1  MEAREPGRPT PTYHLVPNTS QSQVEEDVSS PPQRSSETMQ LKKEISLLNG VSLVVGNMIG
    61  SGIFVSPKGV LVHTASYGMS LIVWAIGGLF SVVGALCYAE LGTTITKSGA SYAYILEAFG
   121  GFIAFIRLWV SLLVVEPTGQ AIIAITFANY IIQPSFPSCD PPYLACRLLA AACICLLTFV
   181  NCAYVKWGTR VQDTFTYAKV VALIAIIVMG LVKLCQGHSE HFQDAFEGSS WDMGNLSLAL
   241  YSALFSYSGW DTLNFVTEEI KNPERNLPLA IGISMPIVTL IYILTNVAYY TVLNISDVLS
   301  SDAVAVTFAD QTFGMFSWTI PIAVALSCFG GLNASIFASS RLFFVGSREG HLPDLLSMIH
   361  IERFTPIPAL LFNCTMALIY LIVEDVFQLI NYFSFSYWFF VGLSVVGQLY LRWKEPKRPR
   421  PLKLSVFFPI VFCICSVFLV IVPLFTDTIN SLIGIGIALS GVPFYFMGVY LPESRRPLFI
   481  RNVLAAITRG TQQLCFCVLT ELDVAEEKKD ERKTD

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against SLC7A6 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 12
Mean surface accessibility (rSASA): 0.26
Highest tissue expression: 67 nTPM

Expression across tissuesHPA

Tissue

skeletal muscle: 67 nTPM
thymus: 35 nTPM
adipose tissue: 32 nTPM
breast: 26 nTPM
tongue: 25 nTPM
tonsil: 20 nTPM

Single-cell type

thymic myoid cells: 738 nCPM
myonuclei: 318 nCPM
adipocytes: 307 nCPM
choroid plexus epithelial cells: 224 nCPM
syncytiotrophoblasts: 187 nCPM
alveolar cells type 1: 157 nCPM

Immune cell

plasmacytoid DC: 17 nTPM
naive CD4 T-cell: 12 nTPM
NK-cell: 7.1 nTPM
memory B-cell: 6.7 nTPM
naive CD8 T-cell: 6.7 nTPM
memory CD4 T-cell: 6.5 nTPM

Brain region

choroid plexus: 49 nTPM
cerebellum: 26 nTPM
cerebral cortex: 19 nTPM
hippocampal formation: 19 nTPM
thalamus: 17 nTPM
hypothalamus: 17 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.66
gnomAD pLI: 0.01
gnomAD missense Z: 1.34
DepMap mean gene effect: -0.1
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

amino acid transmembrane transporter activity
arginine binding
basic amino acid transmembrane transporter activity
L-amino acid transmembrane transporter activity
L-arginine transmembrane transporter activity
L-lysine:L-arginine antiporter activity

Cellular components

plasma membrane

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of SLC7A6 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

SLC3A2

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads SLC7A6 as an antibody target. Whether an autoantibody or antibody against SLC7A6 could matter depends on whether native SLC7A6 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

SLC7A6 is annotated at the cell surface, where native SLC7A6 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label SLC7A6 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...